Accessibility Help | Sitemap | Contact Us | Customer Support CALL 1-800-275-4524
United States Change Country
Home  |  Conditions  |  Products  |  Clinical Evidence  |  Education and Training  |  For Patients  |  Customer Support  |  Suppliers
You are here: Home > About KCI > News & Media > First International Consensus Guidelines Published for KCI Negative Pressure Wound Therapy with Instillation
Print

First International Consensus Guidelines Published for KCI Negative Pressure Wound Therapy with Instillation

Released : January 8th 2014

Guidelines Published in Journal of Plastic and Reconstructive Surgery

KCI, Leader in Advanced Wound Care Solutions

SAN ANTONIO, Texas, Jan. 8, 2013 – Kinetic Concepts, Inc. (KCI) announced today the publication of the first International Consensus Guidelines for its Negative Pressure Wound Therapy with Instillation (NPWTi).1 The guidelines appeared in the December issue of the Journal of Plastic and Reconstructive Surgery.

“As the body of evidence continues to grow in support of NPWTi, these clinical guidelines written by world-renowned key opinion leaders in wound care will help to further advance proper usage of V.A.C.VeraFlo™ Therapy to improve patient outcomes,” said Dr. Ron Silverman, Chief Medical Officer, KCI.

The international consensus panel, convened by MedStar Georgetown University Hospital (through an unrestricted educational grant from KCI), provides the first authoritative guidance on the appropriate use of NPWTi. The guidelines include nine major consensus statements that provide clinical guidance in the following areas:

  • Appropriate wound types that would benefit from instillation therapy
  • Importance of debridement for acutely infected, chronically infected, or contaminated wounds
  • Appropriate instillation solutions, volume of solution and soak time
  • Appropriate pressure settings and modes
  • Optimal duration of NPWTi

“Over the past decade, innovations in wound care such as NPWT, have vastly improved patient experiences and outcomes,” said Dr. Christopher Attinger, Interim Chairman for the Department of Plastic Surgery at Georgetown University. “The addition of instillation greatly expands the possibilities of this unique modality. However, there remains a lack of guidance and data for its proper use. These best practice guidelines will help to educate providers on how and when to properly administer the technology. They should also foster additional research and data on its clinical benefits that, we hope, will lead to faster recovery and reduced complications for patients.”

Negative-Pressure Wound Therapy with Instillation: International Consensus Guidelines” is available in print or by visiting www.PRSJournal.com. The guidelines represent the collective opinions, derived from literature and practice support, of medical experts in the field, including panel experts Paul J. Kim, D.P.M., M.S., Christopher E. Attinger, M.D., John S. Steinberg, D.P.M., Karen K. Evans, M.D., Burkhard Lehner, M.D., Christian Willy, M.D., Ph.D., Larry Lavery, D.P.M., M.P.H., Tom Wolvos, M.D., M.S., Dennis Orgill, M.D., Ph.D., William Ennis, D.O., M.B.A., John Lantis, M.D., Allen Gabriel, M.D. and Gregory Schultz, Ph.D.

V.A.C.VeraFlo™ Negative Pressure Wound Therapy combines the benefits of V.A.C.® Therapy with automated topical solution distribution and removal. V.A.C.VeraFlo™ Therapy is the only therapy that offers specialized instillation dressings and volumetrically delivered solutions with an adjustable soak time. To learn more about KCI and V.A.C.VeraFlo™ Therapy, visit www.KCI1.com.

 

About KCI

Kinetic Concepts Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. KCI, along with LifeCell Corporation and Systagenix Wound Management, form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives. Headquartered in San Antonio, Texas, the company is a leader in the medical technology industry with the most comprehensive offering of best-in-class surgical and chronic wound therapies. Additional information about KCI and its products is available at www.KCI1.com.

 

For more information, contact:
Mike Barger
KCI Corporate Communications
Phone: 210-255-6824
Email: mike.barger@kci1.com

 

1. Kim PJ, Attinger CE, Steinberg JS, et al. Negative-Pressure Wound Therapy with Instillation: International Consensus Guidelines. Plast. Reconstr. Surg.2013; 132: 1567-1579.


  • KCI Express
  • Share on Facebook.com
  • Share on Twitter
  • Visit our YouTube page